BBX-PET Scanner

K210450 · Prescient Imaging, LLC · KPS · Mar 17, 2021 · Radiology

Device Facts

• Record ID: K210450
• Device Name: BBX-PET Scanner
• Applicant: Prescient Imaging, LLC
• Product Code: KPS · Radiology
• Decision Date: Mar 17, 2021
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 892.1200
• Device Class: Class 2
• Attributes: 3rd-Party Reviewed

Intended Use

BBX™-PET scanner is intended to obtain positron emission tomography (PET) images of parts of the human body that fit in the patient aperture (e.g., head) to detect abnormal pattern of radioactivity after injection of a positron emitting radiopharmaceutical. This information can assist in research, diagnosis, therapeutic outcome assessment.

Device Story

BBX-PET Scanner is a PET imaging system for human or animal use; captures gamma rays emitted by injected radiopharmaceuticals. System consists of a gantry with scintillation detectors and a universal console workstation; connected via optical fiber and USB. Detectors (Lutetium Fine-Silicate crystals coupled to solid-state photomultipliers) arranged on a 29 cm diameter cylindrical shell; detect annihilation photons to form coincidence events based on timing, energy, and position. Electronic circuits digitize signals; workstation software performs image reconstruction and display. Used in clinical settings by trained personnel. Output images represent internal radioactivity distribution; assists clinicians in diagnosis, therapeutic planning, and outcome assessment. Benefits include non-invasive visualization of physiological processes.

Clinical Evidence

Bench testing performed per NEMA NU-2:2012 standards (spatial resolution, scatter fraction, count losses, randoms, sensitivity, accuracy, image quality). Electrical safety and EMC testing per IEC 60601-1 and IEC 60601-1-2. Clinical effectiveness supported by sample images from three clinical cases.

Technological Characteristics

PET scanner; 29 cm diameter cylindrical gantry. Detectors: Lutetium Fine-Silicate (LFS) scintillators coupled to solid-state photomultipliers. Connectivity: optical fiber and USB to workstation. Software: image acquisition, reconstruction, display, network transfer. Attenuation correction: calculated method. Standards: IEC 60601-1 (electrical safety), IEC 60601-1-2 (EMC), NEMA NU-2:2012 (performance).

Indications for Use

Indicated for obtaining PET images of human body parts (e.g., head) fitting within the patient aperture to detect abnormal radioactivity distribution following injection of positron-emitting radiopharmaceuticals. Used for research, diagnosis, therapeutic planning, and outcome assessment.

Regulatory Classification

Identification

An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.

Predicate Devices

• NeuroPET (K091269)

Submission Summary (Full Text)

{0}------------------------------------------------

March 17, 2021

Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Prescient Imaging, LLC % Mr. Dave Yungvirt CEO Third Party Review Group, LLC 25 Independence Blvd WARREN NJ 07059

Re: K210450

Trade/Device Name: BBX-PET Scanner Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: Class II Product Code: KPS Dated: February 12, 2021 Received: February 16, 2021

Dear Mr. Yungvirt:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

{1}------------------------------------------------

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

For

Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K210450

Device Name BBX™ -PET Scanner

### Indications for Use (Describe)

BBX™-PET scanner is intended to obtain positron emission tomography (PET) images of parts of the human body that fit in the patient aperture (e.g., head) to detect abnormal pattern of radioactivity after injection of a positron emitting radiopharmaceutical. This information can assist in research, diagnosis, therapeutic outcome assessment.

Type of Use (Select one or both, as applicable)

| Prescription Use (Part 21 CFR 801 Subpart D) | <span style="font-size: 20px;">☑</span> |
|----------------------------------------------|-----------------------------------------|
| Over-The-Counter Use (21 CFR 801 Subpart C) | <span style="font-size: 20px;">☐</span> |

## CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

## *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

## K210450

## SECTION 5- 510(K) SUMMARY

#### I. SUBMITTER INFORMATION

Submitter Prescient Imaging LLC., 12569 Crenshaw Blvd Hawthorne, CA-90250

Farhad Daghighian, Ph.D. & Jeffrey Chou Contact Person 12569 Crenshaw Blvd, Hawthorne CA-90250 Phone: [phone] [e-mail] Date 03/10/2020

#### II. DEVICE IDENTIFICATION

| Trade/ Proprietary Name | BBX™-PET Scanner |
|-------------------------|-------------------------------------|
| Common Name | PET Scanner |
| Classification Name | Emission computed tomography system |
| 21 CFR Reference | 892.1200 |
| Classification | Class II |
| Panel | Radiology |
| Product Code | KPS |

#### III. IDENTIFICATION OF PREDICATE DEVICE

## Predicate Device

NeuroPET

510(k) number: K091269

Applicant: PhotoDetection Systems, Inc.

This predicate has not been subject to a design-related recall.

{4}------------------------------------------------

#### IV. DEVICE DESCRIPTION

The BBX-PET Scanner is a Positron Emission Tomography (PET) system to image the distribution of injected positron emitting radiopharmaceuticals into live humans or animals. The BBX-PET Scanner produces images that represent the internal distribution of radioactivity in the head. The BBX-PET Scanner is comprised of two parts; the Gantry containing detectors and electronics, and the Universal Console that contains the computer workstation. These two parts are connected to each other using optical fiber and an USB cable. The detector assembly is composed of scintillation crystal Lutetium Fin-Silicate (LFS) and light detector photomultiplier. These detectors are arranged on the surface of a cylindrical shell with the diameter of 29 cm in the Gantry. Various electronic circuits are used to process and digitize the signals of these detectors and process the data and store in the computer of the Universal Console for image reconstructions and display.

#### V. INDICATIONS FOR USE

BBX™-PET scanner is intended to obtain positron emission tomography (PET) images of parts of the human body that fit in the patient aperture (e.g., head) to detect abnormal pattern of distribution of radioactivity after injection of a positron emitting radiopharmaceutical. This information can assist in research, diagnosis, therapuetic planning and therapeutic outcome assessment.

Both the subject and predicate device have the same intended use for obtaining positron emission tomography (PET) images of parts of the human body that fit in its patient aperture. Also, their field of views are very similar and suitable for brain imaging.

The few minor differences between the BBX-PET and the predicate device do not alter the intended use of the device nor do they affect the safety and effectiveness of the BBX-PET relative to the predicate.

{5}------------------------------------------------

#### VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE

Both scanners are Positron Emission Tomography systems used to image and measure the distribution of injected positron emitting radiopharmaceuticals in human beings. The PET Scanners both produce images that represent the internal distribution of radioactivity in the head or other body parts that fit in the similar field of view. At a high level, the subject and predicate devices are based on the following same technological elements:

- The PET detectors are arranged on a cylindrical shell with inner diameter of 29 cm vs. 31 cm.
- . The detectors detect gamma rays that are emitted by radioactivity placed inside this cylinder.
- . The detectors consist of scintillators and photomultipliers.
- . The detectors detect the gamma rays and the coincidence events are formed based on timing, energy and position of detection of the annihilation photons in the detectors.
- . Software acquires, displays and transfers these images to a networkserver.
- . Both PET scanners use calculated attenuation correction method.

The following technological differences exist between the subject and predicate devices:

- . BBX-PET scintillators are lutetium fine-silicate (LFS), optically coupled to solid- state photomultipliers.
- The predicate device uses detectors consisting of blocks of 16x10 Csl(Na) scintillators, attached to photomultiplier tubes.

#### PERFORMANCE DATA VII.

The following performance data were provided in support of the substantial equivalence determination.

#### i. Electrical safety and electromagnetic compatibility (EMC)

Electrical safety and EMC testing were conducted on the BBX™-PET scanner. The system complies with the IEC 60601-1: 2005 (Third Edition) + COOR.1:2006 + CORR.2:2007 + A1:2012 Medical electrical equipment -- Part 1: General requirements for basic safety and essential performance

{6}------------------------------------------------

for electrical safety and the IEC 60601-1-2 ed 4.0 (2014-02) Medical electrical equipment – Part 1-2: General requirements for basic safety and essential performance – Collateral Standard: Electromagnetic disturbances – Requirements and tests for EMC.

#### ii. Software Verification and Validation Testing

Software verification and validation testing were conducted, and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (CDRH, 2005)." The software for this device was considered as a "moderate" level of concern, since a malfunction or a latent design flaw might lead to an erroneous diagnosis or a delay in delivery of appropriate medical care that might lead to minor injury.

#### iii. Performance Testing - Bench

Performance testing was conducted, and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff," Guidance for the Submission of Premarket Notifications for Emission Computed Tomography Devices and Accessories (SPECT and PET) and Nuclear Tomography Systems" Section IX.C.2. (CDRH, 1998).

Performance of the BBX™-PET Scanner has been tested by Prescient Imaging LLC according to NEMA NU-2:2012 - Performance Measurements of Positron Emission Tomography. The testing performed include:

- 1. SPATIAL RESOLUTION
- 2. SCATTER FRACTION, COUNT LOSSES, AND RANDOMS MEASUREMENT
- 3. SENSITIVITY
- 4. ACCURACY: CORRECTIONS FOR COUNT LOSSES AND RANDOMS
- 5. IMAGE QUALITY, ACCURACY OF CORRECTIONS

Test results indicate that BBX™- PET Scanner complies with its predetermined specification and the applicable standards.

{7}------------------------------------------------

#### Performance Testing - Clinical Effectiveness iv.

Clinical effectiveness was conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff," Guidance for the Submission of Premarket Notifications for Emission Computed Tomography Devices and Accessories (SPECT and Nuclear Tomography Systems" Section IX.F. (CDRH, 1998).

Sample images from three clinical cases using the BBX™-PET Scanner were provided.

## VIII. CONCLUSIONS

The data support the safety of the device and the hardware and software verification and validation demonstrate that the BBX™-PET Scanner should perform as intended in the specified use conditions. The sample images from three clinical cases supported the clinical effectiveness of the BBX™-PET Scanner. Based upon performance data, BBX™-PET Scanner is substantially equivalent to the predicate device.